US EditionRoche candidate shows early promise for treating haemophilia A - Pharmafile
Summary by pharmafile.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Roche candidate shows early promise for treating haemophilia A - Pharmafile
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational bispecific antibody for haemophilia A. Data presented at the 2025 International Society on Thrombosis and Haemostasis Congress on 21 to 25 June, Washington DC, US, indicates that NXT007 may offer haemostatic normalisation in patients (without factor VIII inhibitors). NXT007, developed […] The post Roche candidate shows early promise for treating …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
